PINL:GRPOF - Post by User
Comment by
Hammertown87on Feb 13, 2019 11:21am
96 Views
Post# 29358185
RE:RE:Not seeing the bounce to $1 are we, need more than luck!
RE:RE:Not seeing the bounce to $1 are we, need more than luck!I think someone hacked his account because he should know this which is coming in 2019.
In the autumn of 2018 Tetra held a Type B meeting with the FDA for the dronabinol AdVersa™ mucoadhesive delivery system, PPP002. Tetra, along with its partner IntelGenx Corp, is developing this product in the United States under the accelerated 505(b)(2) pathway for the indication of chemotherapy-induced nausea and vomiting, and anorexia and weight loss in people with AIDS. The FDA confirmed the eligibility of the 505(b)(2) regulatory pathway for the product PPP002 and that the efficacy and systemic safety would be supported by the corporation’s proposed comparative bioavailability study and, if successful, Tetra could apply for FDA approval in late 2019, for those indications.